• ECS commences Australian distribution of Terphogz strains, including 'The Original Z'
• Terphogz is a globally renowned cannabis genetics brand with award-winning terpene-rich cultivars
• The launch strengthens ECS's premium product portfolio and supports strategic B2C expansion in Australia

ECS Botanics Holdings Ltd (ASX: ECS), a leading medicinal cannabis company, has announced the official launch of Terphogz™ into the Australian medicinal cannabis market. This milestone follows ECS's exclusive eight-year licensing agreement with California-based Terphogz LLC, one of the world's most recognised cannabis breeding groups. The Terphogz product range, including the globally celebrated genetics such as The Original Z™, is now available to prescribers and pharmacies in Australia. The products have been cultivated at a contracted indoor facility and will be distributed through ECS's growing direct-to-consumer (B2C) sales platform, supported by a dedicated medical liaison team and an expanding base of prescribers. This aligns with ECS's broader growth strategy to deliver high-quality, differentiated medicines underpinned by globally respected genetics. ECS Botanics Managing Director, Nan-Maree Schoerie, commented that the launch of Terphogz in Australia reflects the company's commitment to bringing global best-in-class cannabis products to patients and building ECS into a trusted house of brands.